Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis

Kim, Alexander Y.; Frantz, Shelby; Brower, Jayson; Akhter, Nabeel

doi:10.1016/j.jvir.2018.09.020

Cited by 19 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Kim et al recently published multicenter outcomes in 33 patients with metastatic pancreatic adenocarcinoma treated with Yttrium-90 radioembolization. 32 The median survival following radioembolization was 8.1 months and grade III or greater complications were reported in 15% of patients, some of which may have been related to previous chemotherapy (aphthous ulcer formation and neuropathy).…”

Section: Metastatic Diseasementioning

confidence: 96%

Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer

Hevert

Howser

Gould

et al. 2019

Semin intervent Radiol

View full text Add to dashboard Cite

Interventional radiologists have multiple points of involvement in the treatment and management of patients with pancreatic adenocarcinoma. There is increasing interest in cytoreductive treatment of the primary tumor as well as metastatic disease via arterial and ablative techniques. The focus of this article is on the current evidence for pancreatic irreversible electroporation. For patients undergoing curative surgery or terminal palliation, interventional radiology can manage complications and symptoms. In this article, therapeutic and palliative options in this group of patients including postoperative embolization, biliary drainage, and stent placement are reviewed.

show abstract

Section: Metastatic Diseasementioning

confidence: 96%

Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer

Hevert

Howser

Gould

et al. 2019

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…Overall survival was 9 mo. Kim et al [ 98 ] also used Y90-labelled resin microspheres in 33 patients and reported 8.1 mo median OS. Grade 3 adverse events were noted in 2 patients.…”

Section: Minimally Invasive Treatments Of Pancreatic Cancer Liver Metastasesmentioning

confidence: 99%

Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer

Bibok

Kim

Malafa

et al. 2021

WJG

View full text Add to dashboard Cite

Pancreatic cancer is a challenging malignancy with limited treatment options and poor life expectancy. The only curative option is surgical resection, but only 15%-20% of patients are resectable at presentation because more than 50% of patients has distant metastasis at diagnosis and the rest of them has locally advanced pancreatic cancer (LAPC). The standard of care first line treatment for LAPC patients is chemotherapy with or without radiation therapy. Recent developments in minimally invasive ablative techniques may add to the treatment armamentarium of LAPC. There are increasing number of studies evaluating these novel ablative techniques, including radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation. Most studies which included pancreatic tumor ablation, demonstrated improved overall survival in LAPC patients. However, the exact protocols are yet to set up to which stage of the treatment algorithm ablative techniques can be added and in what kind of treatment combinations. Patients with metastatic pancreatic cancer has dismal prognosis with 5-year survival is only 3%. The most common metastatic site is the liver as 90% of pancreatic cancer patients develop liver metastasis. Chemotherapy is the primary treatment option for patients with metastatic pancreatic cancer. However, when the tumor is not responding to chemotherapy or severe drug toxicity develops, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease progression and improve survival in selected patients. During the last decade new therapeutic options arose with the advancement of minimally invasive technologies to treat pancreatic cancer patients. These new therapies have been a topic of increasing interest due to the severe prognostic implications of locally advanced and metastatic pancreatic cancer and the low comorbid risk of these procedures. This review summarizes new ablative options for patients with LAPC and percutaneous liver-directed therapies for patients with liver-dominant metastatic disease.

show abstract

“…The mOS of patients with sole LM was 12.2 months. The results of the study conducted by Kim et al32 achieved a PR of 42% and a SD of 37%, with a mOS of 8.1 months in 33 patients.…”

mentioning

confidence: 91%

Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects

Jin

Dai

2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with increasing incidence and mortality. More than half of PDAC patients develop metastases, with the liver being the most common site. Patients with pancreatic ductal adenocarcinoma with liver metastases (PCLM) have a very limited scope for surgery due to aggressive tumor behavior and poor prognosis. However, with the improvements in preoperative systemic therapy and perioperative outcomes, an increasing number of patients are being considered for surgical management. However, the best choice of surgical treatment and criteria for selecting suitable PCLM patients who may benefit from surgical treatment remains controversial. Palliative local treatments, such as ablation, locoregional chemotherapy, and brachytherapy, which are less invasive and have fewer contraindications and complications, are the preferred alternatives to surgery. The present study reviews the advances in the management of PCLM, with focus on resection and local therapies.

show abstract

Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis

Cited by 19 publications

References 32 publications

Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer

Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer

Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer

Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects

Contact Info

Product

Resources

About